Hexarelin · research summary

Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia.

Journal of cachexia, sarcopenia and muscle · 2017. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Preclinical animal study investigating calcium homeostasis in cisplatin-induced cachexia and the effects of growth hormone secretagogues.
“The aim of this study was to characterize the calcium homeostasis in fast‐twitch EDL muscle of adult rats with cisplatin‐induced cachexia and to establish the potential beneficial effects of two GHS (hexarelin and JMV2894).”

Subjects

Adult male Wistar rats.
“Adult male rats were purchased from Charles River Laboratories (Italy).”

Sample size

Groups of 9–13 animals for general protocols, with specific subgroups of 4 rats for in vivo functional measurements.
“Each animal group was formed by 9–13 animals.”

Duration

5 days, with cisplatin administered on days 1–3 and GHS administered on days 1–5, with sacrifice on day 5.
“Cisplatin was administered on day 1 through 3; hexarelin or JMV2894 was administered from day 1 through 5 (Figure 1).”

Reported findings

Administration of hexarelin or JMV2894 reduced cisplatin-induced alterations in calcium homeostasis and preserved muscle function.
“Administration of hexarelin or JMV2894 markedly reduced the cisplatin‐induced alteration of calcium homeostasis by both common as well as drug‐specific mechanisms of action.”
Cisplatin treatment resulted in a significant reduction of muscle weight and fibre diameter, along with up-regulation of atrogin1/Murf-1 genes.
“Cisplatin‐treated EDL muscle fibres were characterized by a ~18% significant reduction of the muscle weight and fibre diameter together with an up‐regulation of atrogin1/Murf‐1 genes and a down‐regulation of Pgc1‐a gene, all indexes of muscle atrophy”

Source: PubMed 28294567 · DOI 10.1002/jcsm.12185 · all study summaries

Study type

Preclinical animal study investigating calcium homeostasis in cisplatin-induced cachexia and the effects of growth hormone secretagogues.

“The aim of this study was to characterize the calcium homeostasis in fast‐twitch EDL muscle of adult rats with cisplatin‐induced cachexia and to establish the potential beneficial effects of two GHS (hexarelin and JMV2894).”

Reported findings

Administration of hexarelin or JMV2894 reduced cisplatin-induced alterations in calcium homeostasis and preserved muscle function.

“Administration of hexarelin or JMV2894 markedly reduced the cisplatin‐induced alteration of calcium homeostasis by both common as well as drug‐specific mechanisms of action.”

Cisplatin treatment resulted in a significant reduction of muscle weight and fibre diameter, along with up-regulation of atrogin1/Murf-1 genes.

“Cisplatin‐treated EDL muscle fibres were characterized by a ~18% significant reduction of the muscle weight and fibre diameter together with an up‐regulation of atrogin1/Murf‐1 genes and a down‐regulation of Pgc1‐a gene, all indexes of muscle atrophy”